Option chain shows key data for AiXin Life Intl's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AiXin Life Intl.

AiXin Life Intl (OTC:AIXN) Stock, Option Chain

AiXin Life International Inc manufactures, market and sells premium-quality healthcare, nutritional products, and wellness supplements, including herbs and greens, traditional Chinese remedies, functional products, such as weight management products, probiotics, foods, and drinks. The operating segments are products, Pharmacies, Hotels, and manufacturer and sales. It also provides advertising and marketing services to certain manufacturers and distributors of the products it sells.

AIXIN LIFE INTL INC by AiXin Life International, Inc.

AiXin Life International Inc

PRFX

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

General

EHang Signs Cooperation Agreement With The Management Committee of the Torch High-Tech Industrial Development Zone of Weihai City To Establish Industry Collaboration On Pilotless eVTOLs

Billionaire entrepreneur Mark Cuban attempted to invest in popular video-sharing app TikTok in the early stages before it was ever called TikTok, but the company <a href="https://www.benzinga.com/startups/24/12/42618228/mark-cuban-admits-ive-gotten-beat-after-losing-20-million-on-shark-tank-startups">turned him away</a>.
What Happened: According to a CNBC <a href="https://www.cnbc.com/2024/12/26/mark-cuban-tried-to-invest-in-musically-before-it-became-tiktok.html">report</a> citing a recent interview with social media personality Jules Terpak, Cuban once attempted to invest in Musical.ly, the video-sharing app that ultimately became TikTok, because he &#8220;loved&#8221; using the platform.
"I remember when it was Musical.ly and I tried to invest … Oh my god, I loved it because I could just turn it on and there would be 15,000 people live immediately that I could talk to,"&nbsp;Cuban reportedly told Terpak in the interview.
The report indicates that Cuban&#8217;s bid for an investment in Musical.ly was unsuccessful because the company didn&#8217;t need the money and wasn&#8217;t looking to take on any new investors. 
Musical.ly ended up being acquired by TikTok parent company Bytedance for around $800 million in 2017. The video-sharing app then merged into TikTok about a year after the acquisition.
See Also: <a href="https://www.benzinga.com/general/social-media/24/12/42680367/tiktok-on-trial-supreme-court-prepares-to-weigh-national-security-risks">TikTok On Trial: Supreme Court Prepares To Weigh National Security Risks</a>
Cuban prefers the older version of the app that focused on music and dancing. Nowadays, TikTok &#8220;feels more corporate&#8221; and business-focused, especially since the revenue-sharing program launch, Cuban said in the interview. 
"I liked it better when it was dances [and] music … Now it's a business,"&nbsp;he said.
It&#8217;s not clear how much Cuban would have invested in Musical.ly if he were given the opportunity. It&#8217;s also not clear exactly how much he would have made from the investment.
Assuming Cuban could have invested at a similar valuation to what Bytedance paid for Musical.ly in 2017 ($800 million), the investment would have appreciated enormously. According to an Economic Times<a href="https://economictimes.indiatimes.com/tech/technology/tiktok-parent-bytedances-valuation-hits-300-billion-sources-say/articleshow/115380343.cms?from=mdr"> report</a>, TikTok parent company Bytedance valued itself at around $300 billion in a recent buyback offer to investors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/12/42672377/billionaire-mark-cuban-says-he-doesnt-spoil-his-kids-and-tells-them-its-my-money-not-yours">Billionaire Mark Cuban Says He Doesn&#8217;t Spoil His Kids And Tells Them &#8216;It&#8217;s My Money, Not Yours&#8217;</a></li>
</ul>
Photo: Shutterstock.

News

Social Media

Startups

Mark Cuban Wanted To Invest In TikTok Before It Was TikTok: 'Oh My God, I Loved It'

Asset Sales

HMST

HomeStreet Enters Agreement To Sell $990M In Multi-Family Commercial Real Estate Loans To Bank of America

WIIM

LAES

SEALSQ shares are trading higher after the company late Thursday announced it has received formal confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement.

ALERT OCCURS AFTER EARLY WEAKNESS IN STOCK
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="745" height="602" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/26210621/Screen-Shot-2024-12-26-at-4.08.57-PM.png" alt="" class="wp-image-4287" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/26210621/Screen-Shot-2024-12-26-at-4.08.57-PM.png 745w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/26210621/Screen-Shot-2024-12-26-at-4.08.57-PM-300x242.png 300w" sizes="(max-width: 745px) 100vw, 745px" /></figure>
Microstrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
At 10:05 AM on December 26th, a significant trading signal occurred for Microstrategy , Inc. (MSTR) as it demonstrated a Power Inflow at a price of $343.47. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Microstrategy&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Microstrategy&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for MSTR, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $343.47. The returns on the High price ($349.68) and Close price ($341.05) after the Power Inflow were respectively 1.9% and -0.7%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. 
Past Performance is Not Indicative of Future Results

Trading Ideas

MSTR

TradePulse Power Inflow Alert: Microstrategy Inc. (MSTR) Moves up 1.8% After Signal

MYSZ

MySize shares are trading higher after the company announced it anticipates closing 2024 with $8.5 million in revenue and targets $15 million in revenue by 2025.

Earnings

OTLK

Outlook Therapeutics 2024 EPS $(4.06) vs $(4.72) YoY

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.68</td>
<td align="right">0.11</td>
<td align="right">0.13</td>
<td>1.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.75</td>
<td align="right">0.06</td>
<td align="right">0.07</td>
<td>273</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">232.80</td>
<td align="right">-0.80</td>
<td align="right">-0.35</td>
<td>655</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.94</td>
<td align="right">-0.17</td>
<td align="right">-0.35</td>
<td>40.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">139.37</td>
<td align="right">-0.23</td>
<td align="right">-0.17</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">240.43</td>
<td align="right">-0.26</td>
<td align="right">-0.11</td>
<td>7.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">99.00</td>
<td align="right">-0.04</td>
<td align="right">-0.05</td>
<td>720</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 27, 2024

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

Price Target

Analyst Ratings

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

Guidance

MySize Anticipates Closing 2024 With $8.5M In Revenue, Targets $15M In Revenue By 2025

On December&nbsp;24, 2024, Sichuan Jiade Zhigao Technology Co.,&nbsp;Ltd., a limited liability company organized under the laws of the PRC ("Jiade Zhigao"), which is a PRC subsidiary of JIADE LIMITED, a Cayman Islands company (the "Company"), entered into an equity transfer agreement (the "Kunyuan Agreement") with Chengdu Meirusi Technology Co.,&nbsp;Ltd. ("Meirusi"), which is a PRC limited liability company holding 75% of the equity interests in Sichuan Kunyuan Safety Technology Services Co.,&nbsp;Ltd. ("Kunyuan"). Pursuant to the Kunyuan Agreement, Jiade Zhigao agreed to acquire 75% of the equity interests in Kunyuan from Meirusi (the "First Acquisition"). In consideration for the First Acquisition, Jiade Zhigao agreed to pay RMB9,000,000 (approximately $1,234,000) to Meirusi, subject to the satisfaction by Meirusi and Kunyuan of their obligations under the Kunyuan Agreement. The Kunyuan Agreement contains customary covenants, closing conditions, and other obligations and rights of the parties.
On December&nbsp;24, 2024, Jiade Zhigao also entered into an equity transfer agreement (the "Jiazhi Agreement") with Meirusi, the sole shareholder of Sichuan Jiazhi Taizhang Safety Technology Co.,&nbsp;Ltd. ("Jiazhi"). Pursuant to the Jiazhi Agreement, Jiade Zhigao agreed to acquire 100% of the equity interests in Jiazhi from Meirusi (the "Second Acquisition"). In consideration for the Second Acquisition, Jiade Zhigao agreed to pay RMB23,000,000 (approximately $3,153,000) to Meirusi, subject to the satisfaction by Meirusi and Jiazhi of their obligations under the Jiazhi Agreement. The Jiazhi Agreement contains customary covenants, closing conditions, and other obligations and rights of the parties.
The foregoing description of the Kunyuan Agreement and the Jiazhi Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Kunyuan Agreement and the Jiazhi Agreement, which are filed as Exhibit&nbsp;10.1 and Exhibit&nbsp;10.2 to this Form&nbsp;6-K, respectively.
The Kunyuan and Jiazhi Agreements and the transactions contemplated thereby were approved and authorized by the board of directors of the Company on December&nbsp;23, 2024.

JDZG

Sichuan Jiade Zhigao Technology Co. Entered Equity Transfer Agreement With Chengdu Meirusi Technology Co., Under Which Jiade Zhigao Agreed To Acquire 75% Of Equity Interests In Kunyuan From Meirusi; Jiade Zhigao Also Entered Equity Transfer Agreement To Acquire 100% Of The Equity Interests In Jiazhi From Meirusi

BFRG

BullFrog AI Issues Letter to Stockholders: Reflects on Milestones in 2024, Strengthens AI-Driven Drug Development and Expands Collaborations for 2025 Growth

GXAI

Gaxos.ai Announces $4M Registered Direct Offering: Inks Pacts For The Purchase And Sale Of An Aggregate Of 1.34M Shares Of Common Stock At A Purchase Price Of $3.00 Per Share In A Registered Direct Offering Priced At-the-market Under Nasdaq Rules

Management

FAST

Fastenal Announces Senior Executive Vice President And Chief Financial Officer Holden Lewis Provided Notice Of His Resignation, Effective On Apr. 16, 2025

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $184.75, a high estimate of $210.00, and a low estimate of $170.00. Surpassing the previous average price target of $168.86, the current average has increased by 9.41%.
<img src="https://www.benzinga.com/files/images/story/2024/1735304440_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Masimo among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$194.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$193.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Masimo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Masimo compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Masimo's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Masimo's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MASI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Masimo analyst ratings.</a>
<h2>Discovering Masimo: A Closer Look</h2>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Masimo's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Masimo showcased positive performance, achieving a revenue growth rate of 5.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Masimo's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Masimo's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Masimo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Masimo's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.59, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MASI

What Analysts Are Saying About Masimo Stock

KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.45, a high estimate of $41.00, and a low estimate of $30.00. This current average represents a 0.89% decrease from the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1735304428_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of KinderCare Learning among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Faiza Alwy</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KinderCare Learning. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KinderCare Learning compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of KinderCare Learning's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into KinderCare Learning's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KLC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on KinderCare Learning analyst ratings.</a>
<h2>Get to Know KinderCare Learning Better</h2>
KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market- leading footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its three go-to-market channels are KinderCare Learning Centers, KinderCare Education at Work, and Champions.
<h3>Financial Insights: KinderCare Learning</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: KinderCare Learning's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 7.53%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: KinderCare Learning's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.08% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): KinderCare Learning's ROE stands out, surpassing industry averages. With an impressive ROE of 5.9%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): KinderCare Learning's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.38%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 12.62, KinderCare Learning faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For KinderCare Learning

In the latest quarter, 10 analysts provided ratings for Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bright Horizons Family, revealing an average target of $136.1, a high estimate of $162.00, and a low estimate of $102.00. Witnessing a positive shift, the current average has risen by 2.33% from the previous average price target of $133.00.
<img src="https://www.benzinga.com/files/images/story/2024/1735304416_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bright Horizons Family. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$102.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$128.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bright Horizons Family. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bright Horizons Family compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bright Horizons Family's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Bright Horizons Family's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BFAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bright Horizons Family analyst ratings.</a>
<h2>About Bright Horizons Family</h2>
Bright Horizons Family Solutions Inc provides education and care solutions designed to help employers support their employees in managing their work/life balance. The company has three business segments: full-service center-based child care, backup care, and educational advisory services. The vast majority of the company's revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, tuition assistance, and education consulting. The company earns more than half of its revenue in North America.
<h3>Bright Horizons Family's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Bright Horizons Family's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.35%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bright Horizons Family's ROE excels beyond industry benchmarks, reaching 4.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.42%, the company showcases effective utilization of assets.
Debt Management: Bright Horizons Family's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFAM

Beyond The Numbers: 10 Analysts Discuss Bright Horizons Family Stock

Takeda Pharmaceutical Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase) for the treatment of patients <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42697319/takeda-announces-approval-of-hyqvia-10-s-c-subcutaneous-injection-set-in-japan-for-patients-with-a" rel="noreferrer noopener">with agammaglobulinemia or hypogammaglobulinemia.</a>
These conditions, characterized by low or absent antibody levels, result in an increased risk of serious infections. This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option.
HYQVIA combines subcutaneous immunoglobulin (10%) with recombinant human hyaluronidase (rHuPH20), which facilitates larger volume infusions by increasing the dispersion and absorption of immunoglobulin in subcutaneous tissue.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42696705/bitcoin-ethereum-dogecoin-retreat-after-christmas-surge-top-analyst-highlights-what-btc-needs-to-do-to-invalidate-bearish-outlook" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Pull Back After Christmas Rally: Top Analyst Reveals What Happens Next After BTC Fails To Record Daily Close Above $100K</a>
This allows for less frequent dosing, with treatments every 3 to 4 weeks, compared to weekly or bi-weekly infusions with other subcutaneous immunoglobulin treatments.
This flexibility eliminates the need for venous access, offering patients greater convenience.
The approval was based on data from two Phase 3 clinical trials conducted in Japan and North America.
These studies showed that HYQVIA maintained stable IgG levels comparable to intravenous or other subcutaneous immunoglobulin treatments, with manageable side effects such as mild fever and injection site reactions.
Takeda's commitment to offering differentiated immunoglobulin therapies is further demonstrated by this approval, which expands its portfolio in Japan.
The company also continues to invest in local manufacturing to meet the growing demand for plasma-derived therapies as education and diagnosis of immunodeficiencies improve.
Price Action: TAK shares are trading higher by 1.07% to $13.28&nbsp;premarket at last check Friday.
Read Next:&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42690488/are-donald-trumps-ambitious-bitcoin-goals-feasible" target="_blank" rel="noreferrer noopener">Are Donald Trump's Ambitious Bitcoin Goals Feasible?</a></li>
</ul>

Asia

Equities

Markets

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

UBS analyst Jay Sole reiterates On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and maintains $63 price target.

Reiteration

ONON

UBS Reiterates Buy on On Holding, Maintains $63 Price Target

AiXin Life Intl

Comments

AiXin Life Intl

AiXin Life Intl (AIXN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga